Prevalence of phosphodiesterase-5 inhibitor use in the VHA in 2004 and 2005 is twice that of a commercial health plan in 2001

Journal of Managed Care Pharmacy

Volumn 12, Issue 8, 2006, Pages 692-693

  French, Dustin D ^a   Margo, Curtis E ^b   Campbell, Robert R ^a  

^a James A Haley Veterans Hospital   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

DRUG USE; ERECTILE DYSFUNCTION; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LETTER; PATIENT SAFETY; PRACTICE GUIDELINE; REIMBURSEMENT; ADULT; AGED; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG UTILIZATION; GOVERNMENT; IMPOTENCE; MALE; MIDDLE AGED; NOTE; PUBLIC HOSPITAL; UNITED STATES;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADULT; AGED; DRUG UTILIZATION; HOSPITALS, VETERANS; HUMANS; IMPOTENCE; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 33847263624     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.8.692     Document Type: Letter

References (12)

1. Cooke CE, Wong W, Lee H. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. J Manag Care Pharm. 2005;11(8):674-80. Available at: http://www.amcp.org/data/jmcp/ Original%20Research%20674-680.pdf. Accessed October 10, 2006.
2. FDA approves new drug for treatment of erectile dysfunction in men (FDA Talk Paper, T03-63). Available at: http://www.fda.gov/bbs/topics/ANSWERS/2003/ ANS01249.html. Accessed October 10, 2006.
3. FDA approves third drug to treat erectile dysfunction (FDA Talk Paper, T03-79). Available at: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01265.html. Accessed October 10, 2006.
4. VHA PBM Medical Advisory Panel EZ Minutes. Vol. 3, iss. 4, October-December 2005. Available at: http://www.pbm.va.gov/ezminutes/ EZMinutesOct-Dec05.pdf#search=%22VHA%20PBM%20Levitra%22. Accessed October 10, 2006.
5. Wilson EC, McKeen ES, Scuffham PA, Brown MC, Wylie K, Hackett G. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Pharmacoeconomics. 2002;20(13):879-89.
6. Sullivan F, Donnelly L, Donnan P. A retrospective, study of prescribing for erectile dysfunction in a UK population during 1997-2000: demand was neither excessive nor continuing to rise. Pharmacoepidemiol Drug Safety. 2004;13(8):557-62.
7. Curtiss FR. United States, the last venue for direct-to-consumer advertising, props up the erectile dysfunction market. J Manag Care Pharm. 2005;11(2):176-77. Available at: http://www.amcp.org/data/jmcp/ Editorial%20Subjects-172-177.pdf. Accessed October 10, 2006.
8. Flower R. Lifestyle drugs: pharmacology and the social agenda. Trends Pharmacol Sci. 2004;25(4):182-85.
9. VA Technology Assessment Program VATAP: Treatment options for male erectile dysfunction. Available at: http://www.va.gov/VATAP/topic_ed.htm. Accessed October 10, 2006.
10. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel: the primary care management of erectile dysfunction. Available at: http://www.pbm.va.gov/guidelines/edguidelines.pdf. Accessed October 10, 2006.
11. Thomson Micromedex Healthcare Series. 1974-2006. Vol. 129. Available at: http://www.micromedex.com. Accessed September 20, 2006.
12. Margo CE, French DD. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors. Am J Ophthalmol. 2006; Available ahead of print at: http://ajo.com/inpress. Accessed October 12, 2006.